| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1998PNAS...95.1184S |
| P356 | DOI | 10.1073/PNAS.95.3.1184 |
| P932 | PMC publication ID | 18713 |
| P698 | PubMed publication ID | 9448306 |
| P5875 | ResearchGate publication ID | 13783018 |
| P2093 | author name string | K L Davis | |
| L Feldman | |||
| A J Sytkowski | |||
| E D Lunn | |||
| S Siekman | |||
| P2860 | cites work | A simple microassay for erythropoietin based on 3H-thymidine incorporation into spleen cells from phenylhydrazine treated mice | Q71824797 |
| Isolation and characterization of genomic and cDNA clones of human erythropoietin | Q24299960 | ||
| Cloning and expression of the human erythropoietin gene | Q24608978 | ||
| Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A | Q27732820 | ||
| Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial | Q34182887 | ||
| Purification of human erythropoietin | Q34777478 | ||
| Human erythropoietin gene: high level expression in stably transfected mammalian cells and chromosome localization | Q36458416 | ||
| Homodimerization and constitutive activation of the erythropoietin receptor | Q36883996 | ||
| Erythropoietin receptors induced by dimethyl sulfoxide exhibit positive cooperativity associated with an amplified biologic response | Q37449416 | ||
| Potentiation of the erythropoietin response by dimethyl sulfoxide priming of erythroleukemia cells: evidence for interaction of two signaling pathways | Q41712478 | ||
| The in vivo metabolism of recombinant human erythropoietin in the rat. | Q41887319 | ||
| Recombinant human erythropoietin (rHuEPO): cross-linking with disuccinimidyl esters and identification of the interfacing domains in EPO. | Q42174090 | ||
| Clinical pharmacology of recombinant human erythropoietin (r-HuEPO). | Q44339056 | ||
| Structural characterization of human erythropoietin | Q44404823 | ||
| Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. | Q54096433 | ||
| Isolation and characterization of an anti-peptide monoclonal antibody to human erythropoietin. | Q54134332 | ||
| Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. | Q54718734 | ||
| Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers | Q68577994 | ||
| Denaturation and renaturation of human erythropoietin | Q71390944 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | erythropoietin | Q218706 |
| P1104 | number of pages | 5 | |
| P304 | page(s) | 1184-1188 | |
| P577 | publication date | 1998-02-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Human erythropoietin dimers with markedly enhanced in vivo activity | |
| P478 | volume | 95 |
| Q37257038 | A DNA nanostructure platform for directed assembly of synthetic vaccines |
| Q28484875 | Atypical features of Thermus thermophilus succinate:quinone reductase |
| Q37201897 | CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools |
| Q55312853 | Cell-free protein synthesis as a novel tool for directed glycoengineering of active erythropoietin. |
| Q38028315 | Current state and perspectives on erythropoietin production |
| Q34180647 | Enhancement of therapeutic protein in vivo activities through glycoengineering |
| Q38121067 | Erythropoiesis stimulating agents: approaches to modulate activity |
| Q34606348 | Erythropoietin after a century of research: younger than ever |
| Q38003106 | Erythropoietin and erythropoiesis stimulating agents |
| Q50216954 | Molecular Design, Expression and Evaluation of PASylated Human Recombinant Erythropoietin with Enhanced Functional Properties |
| Q38192002 | New treatment approaches in chronic kidney disease-associated anaemia |
| Q37335059 | Optimizing the management of renal anemia: challenges and new opportunities |
| Q46292739 | Pharmacokinetic and toxicity study of intravitreal erythropoietin in rabbits |
| Q34974011 | Pharmacokinetics and pharmacodynamics of recombinant human EPO-Fc fusion protein in vivo |
| Q38848944 | Probing protease sensitivity of recombinant human erythropoietin reveals α3-α4 inter-helical loop as a stability determinant. |
| Q51822227 | Quantifying Western blots: pitfalls of densitometry. |
| Q34725972 | Survival and proliferative roles of erythropoietin beyond the erythroid lineage |
| Q35050690 | Synthetic covalently linked dimeric form of H2 relaxin retains native RXFP1 activity and has improved in vitro serum stability. |
| Q92117982 | The Influence of Dimerization on the Pharmacokinetics and Activity of an Antibacterial Enzyme Lysostaphin |
| Q35013346 | The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. |
| Q48089546 | Thrombin-Inhibiting Anticoagulant Liposomes: Development and Characterization. |
Search more.